Trial Profile
Optimizing Ponatinib USe (OPUS). A GIMEMA Phase 2 Study of the Activity and Risk Profile of Ponatinib, 30 mg Once Daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients Resistant to Imatinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms GIMEMA; OPUS
- 04 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Feb 2023.
- 16 Aug 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 16 Aug 2021 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2021.